Market Newsdesk

TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, will be conducting 1×1 meetings with investors during the 33^rd Annual Roth Conference being held virtually from March 15^th – March 17^th, 2021.

This year’s event will consist of 1-on-1 / small group meetings, analyst-selected virtual fireside chats, thematic industry panels, and selected Companies on-demand presentations. Institutional investors interested in one-on-one meetings with Medexus management should contact their ROTH Capital institutional sales representative.  

About Medexus Pharmaceuticals Inc.

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: [email protected]

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-344-8765
E-mail: [email protected]

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
E-mail: [email protected]

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SAN DIEGO, CA, March 08, 2021 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biotechnology company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).

“The initiation of this MS Phase 2 study is another important milestone for our lead product candidate, EHP-101,” said Joachim Schupp, M.D., Dr. med., EHP’s Chief Medical Officer. “We have finalized the trial design with our MS Clinical Advisory Board members, who are globally-recognized key clinical opinion leaders in the treatment of MS. We will soon be seeking regulatory approvals to begin the study and look forward to starting clinical site initiations and enrolling multiple sclerosis patients later this year.”

The MS Phase 2 study is an open label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s lead product candidate, EHP-101, an oral formulation of a patented new synthetic molecule, in patients with relapsing forms of multiple sclerosis (RMS).  The study is planned to enroll approximately 50 patients who suffer from RMS (relapsing-remitting and relapsing secondary progressive MS) in approximately 20 study centers in the United States and Australia.  Escalating doses administered once or twice daily are planned to be evaluated over a treatment duration of 24 weeks. The dose levels were established based on previous successful 6 and 9-month animal toxicity studies and a Phase 1 human study in 104 healthy subjects, all showing a good safety and tolerability profile.

Along with assessments of safety and tolerability, efficacy endpoints in the Phase 2 MS study will include the changes from baseline in brain lesion activity as measured by MRI; disease progression and disability status, as well as the proportion of relapse-free patients, patient-reported outcomes, and assessments of several biomarkers such as changes in the neurofilament light chain (NfL) levels in the blood, which is a promising diagnostic, prognostic and monitoring biomarker used in assessing neurological diseases.

In 2020, the company presented promising remyelination (restoration of the protective myelin sheath around the nerves) data in animal models of MS at the Americas Committee for Treatment in Multiple Sclerosis (ACTRIMS) conference.

Jim DeMesa, M.D., M.B.A., EHP’s President and CEO added, “This MS clinical study is the second Phase 2 study we are conducting with EHP-101. Our other Phase 2 study is in systemic sclerosis, a severe form of scleroderma, which is enrolling patients in the United States, Australia and New Zealand. These two Phase 2 studies provide us the opportunity for significant clinical milestones in 2022 and beyond.”

EHP is also continuing preclinical development of its second compound, EHP-102, with an initial focus on Huntington’s disease and Parkinson’s disease.

About Multiple Sclerosis and EHP-101

Multiple sclerosis is an inflammatory and demyelinating disorder of the central nervous system affecting an estimated 2.3 million people worldwide. Myelin is a sheath around nerves that aids in conducting nerve impulses. Demyelination is a breakdown of this sheath and in people with MS it is not reversible naturally or through existing therapies. As MS progresses, it affects muscles, nerves, and joints, causing significant pain, as well as spasms, stiffness, difficulty chewing, swallowing, and speaking. Currently, approved MS drugs are all primarily intended to relieve symptoms and reduce the rate of relapses, but none are curative.

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing proprietary product candidates to treat CNS, autoimmune, and other diseases. The Company’s technology platform consists of two families of patented new chemical entities derived from synthetic cannabidiol (CBD) and cannabigerol (CBG), two of the non-psychoactive cannabinoids, chemically modified through rational drug design to create new molecules that affect validated receptors and pathways in the body which are pertinent to targeted diseases. EHP-101 is in Phase 2 clinical development for the treatment of systemic sclerosis, a severe form of scleroderma, and multiple sclerosis. It has received Orphan Drug designation in the US and EU and Fast Track status in the US for systemic sclerosis. EHP-102 is in preclinical development and focused on treating Parkinson’s disease and Huntington’s disease. It has received Orphan Drug designation in the US and EU for Huntington’s disease. For more information, go to http://www.emeraldpharma.life or contact EHP via email at [email protected].

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products

GREENWICH, Conn., March 08, 2021 (GLOBE NEWSWIRE) — Fieldpoint Private, the fast-growing wealth advisory and private banking boutique serving families and institutions, announced it has surpassed the $1 billion threshold in total bank assets, and $5 billion in total wealth management assets.

The 12-year-old firm now ranks within the top 20 percent of U.S. banks by assets, and was recently named among America’s top 100 independent investment firms by Barron’s magazine. Since its 2008 founding in Greenwich, Connecticut, Fieldpoint Private has grown its presence to include New York City, Georgia and Florida, earning the business of families, entrepreneurs, businesses and charitable institutions in 46 states. It has attracted leadership, advisors and bankers from Bank of America, BNY Mellon, Brown Brothers Harriman, Citigroup, Goldman Sachs, J.P. Morgan, Morgan Stanley, Merrill Lynch, Neuberger Berman, Wells Fargo and others, as well as deeply rooted community banks.

Chairman and CEO Tim Tully said that while it is important to take a moment to recognize these milestones, growth – by itself – was never the firm’s mandate. “Our goal has always been to create a new standard of service for clients, to maintain independence of thought and protect our commitment to do what’s right for the client, wherever that takes us.” He added, “It’s clearly taking us to a pretty good place, and I’m grateful to our colleagues for all they have done to get us here, and to our clients for their trust and enthusiasm along the way.”

Russell Holland, President and CEO of Fieldpoint Private’s banking unit, said that when Fieldpoint was founded, clients could get commercial and personal banking, along with investment advice at any number of the giant global firms. “But clients felt the advice and experience was disconnected and too often met the interests of the firm more than themselves and their families,” he said.

Christopher DeLaura, President and CEO of the firm’s wealth management unit added, “Delivering all of this, in a boutique experience, with fully integrated advice and world-class intellectual capital, was something no one had tried before. These milestones tell us it was an important idea at the right time, and we feel like we are just getting started.”

About Fieldpoint Private

Headquartered in Greenwich, Connecticut, Fieldpoint Private (www.fieldpointprivate.com) is a boutique financial firm providing the highest degree of personalized, confidential wealth planning and private banking services. Catering to highly successful individuals, families, businesses and institutions, Fieldpoint Private offers a powerful combination of wealth management and strategy, family office, private banking and business banking services addressing every financial need for each of our clients including: wealth transfer advice, tax planning, aggregation and performance reporting, risk management, goals-based investing strategies, sophisticated investment selection, discreet and personalized banking, highly customized credit solutions, custom custody and trust solutions, highly attentive and responsive service, and concierge services.

Fieldpoint Private was established in 2008 by 31 Founders with a specific vision and purpose. These extraordinary leaders of industry and community recognized the opportunity to create a financial firm totally attuned to people’s individual circumstances. Our firm is built on a philosophy of exclusive membership and client-centricity. Working with a limited number of relationships gives every person the experience of belonging to an extremely selective group. The result is a new breed of institution established on the basis of personalization, responsiveness, and exclusivity, and an ensured commitment to impeccable service and consistently flawless execution. Our service approach offers a unique client experience custom crafted to each client’s financial needs.

Banking Services: Fieldpoint Private Bank & Trust
Registered Investment Advisors: Fieldpoint Private Securities, LLC, is a SEC Registered Investment Advisor and Broker Dealer. Member FINRA, MSRB, SIPC.

Media Contact:
Michael White
Chief Marketing Officer
Fieldpoint Private
203.413.9340 
[email protected]

SAN FRANCISCO and TORONTO, March 08, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced the formation of a Scientific Advisory Board (“SAB”) that will work closely with Claritas’ management team to develop nitric oxide-based therapeutics to treat diseases and disorders with significant unmet medical need. The SAB will be led by Dr. Garry J. Southan, an internationally renowned expert in the biology, biochemistry, and chemistry of nitric oxide.

A synthetic chemist by training, Dr. Southan has an extensive experience and publication record in nitric oxide synthase (NOS) and in the chemistry of NOS inhibitors, nitric oxide adducts, and nitric oxide donor compounds. He has successfully identified, synthesized, and characterized a wide variety of novel NOS inhibitors as well as nitric oxide donor compounds. He is also the author of invited reviews and more than 100 peer-reviewed scientific publications and 25 patents, and an invited speaker at international meetings on the topic of NOS inhibitors and nitric oxide donors.

For his post-doctoral studies, Dr. Southan spent 3 years with the Nobel Laureate Sir John R. Vane, FRS at the William Harvey Research Institute in London, England to study the biochemistry of nitric oxide and nitric oxide synthases. Dr. Southan worked with Sir John Vane at the time when interest in nitric oxide as a vascular mediator was developing. As the only recognized chemist in the William Harvey Research Institute, he was required to explain why certain compounds prolonged the effects of “endothelial derived relaxing factor” (EDRF) on ex-vivo tissues. In the course of these studies, he showed that EDRF is in fact nitric oxide, and, subsequently, that nitric oxide associated with these hydroxyguanidine compounds to stabilize its activity. While investigating this interaction, he isolated and ultimately characterized a novel class of resonance-stabilized compounds formed by the reaction of nitric oxide and nitric oxide-related species with hydroxyguanidines. These compounds decompose in solution to release nitric oxide and nitrous oxide. Nitric oxide is produced in vivo by the NOS family of enzymes. Using 15N labeled substrates and high-resolution mass-spectrometry, he was able to confirm that nitric oxide synthase utilizes the hydroxylated guanidino nitrogen of N-hydroxyarginine for the generation of nitric oxide. At the same time, he discovered novel classes of inhibitors of nitric oxide synthase and nitric oxide generation, which had beneficial effects in models of inflammation and ischemic/reperfusion disease.

Dr. Southan’s studies on nitric oxide synthase inhibitors continued when he was invited to help establish a research laboratory in the Division of Critical Care at the Children’s Hospital in Cincinnati, Ohio. His work there focused on finding therapies for some of the more intractable diseases and infections in the pediatric intensive care unit based on novel inhibitors that were selective for the inducible NOS isoform (iNOS). Many of the inhibitors he discovered were made available to the research community and were used in the study of the physiological and pharmacological actions of nitric oxide. Hundreds of articles have been published using his isothiourea-based inhibitors alone.

Dr. Southan later worked at the National Cancer Institute in the laboratory of Larry Keefer, a leading group in the development of novel nitric oxide adducts. In addition, he studied other forms of nitric oxide and its downstream biological products in order to find deactivators of reactive oxygen/nitrogen species such as superoxide, peroxynitrite and nitroxyl.

Following his research at the National Cancer Institute, Dr. Southan co-founded Inotek Pharmaceuticals Corporation, where his initial responsibility was to provide novel pharmacological tools for the study of inflammatory, reperfusion and related diseases. His basic research on poly(ADP-ribose) polymerase (“PARP”) inhibitors led to development of several clinical compound candidates. Six of his compounds, targeting different mechanisms, were taken through the investigational new drug (IND) process and into clinical trials. He was responsible for the pre-clinical chemistry and provision of GMP materials for the clinical trials. One of these compounds (INO-1001) was the first PARP inhibitor to enter clinical trials and was subsequently licensed to Genentech for $600 million in 2006.

Dr. Southan then took a position at Radikal Therapeutics for 12 years, as Senior Vice-President of Research, where he led the analytical and bioanalytical chemistry divisions. During this time, he was responsible, in conjunction with Dr. Prakash Jagtap, for the invention of R-107, a novel nitric oxide donor and peroxynitrite decomposition catalyst, as well as other new chemical entities regulating diseases involved with vascular tone, inflammation, and reactive oxygen species. Dr. Southan was awarded numerous grants and contracts to study and develop R-107, supported initially by the National Institutes of Health and later by the Biomedical Advanced Research and Development Authority (BARDA).

Upon the licensing of the R-107 COVID-19 program to Claritas Pharmaceuticals, Dr. Southan became an independent consultant to the pharmaceutical industry where he brings three decades of experience in drug discovery and development in the field of nitric oxide and free radical biochemistry.   

“The scientific guidance of Dr. Southan will be invaluable as we focus on bringing nitric oxide therapies into the clinic for the benefit of patients,” stated Robert Farrell, President and CEO of Claritas. “The potential of nitric oxide in various disease settings has been extensively validated in multiple small and large animal studies. Nevertheless, the use of nitric oxide has been limited due to the fact that it is a gas that is difficult and impractical to adminsiter. We are excited to work with this world-class expert in nitric oxide pharmacology as we move forward with R-107 to transform nitric oxide therapy into a practical and easily administered treatment for multiple diseases and disorders.”

About Claritas Pharmaceuticals

Claritas Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need, and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people’s lives.

• Website Home: https://claritaspharma.com/
• News and Insights: https://claritaspharma.com/news/
• Investors: https://claritaspharma.com/investors

Cautionary Statements


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives, and other statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the ris
k that future clinical studies may not proceed as expected or may produce unfavorable results. Claritas
undertakes no obligation to comment on analyses, expectations or statements made by third parties, its securities, or financial or operating results (as applicable). Although Claritas believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Claritas’ control. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Claritas disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. 

Contact Information

Robert Farrell
President, CEO
(888) 861-2008
[email protected]

BETHESDA, Md., March 08, 2021 (GLOBE NEWSWIRE) — Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust (“REIT”), today announced that it will present to investors attending Citi’s 2021 Virtual Global Property CEO Conference on Tuesday, March 9 at 2:45 p.m. ET. Jim Risoleo, President and Chief Executive Officer, will participate in a company roundtable presentation led by a Citi research analyst.

In conjunction with the roundtable presentation, the Company has published a March 2021 investor update located in the Investor Relations section of the Company’s website ahead of the conference (https://www.hosthotels.com/investor-relations/investor-presentation).

About Host Hotels & Resorts

Host Hotels & Resorts, Inc. is an S&P 500 company and is the largest lodging real estate investment trust and one of the largest owners of luxury and upper-upscale hotels. The Company currently owns 75 properties in the United States and five properties internationally totaling approximately 46,300 rooms. The Company also holds non-controlling interests in six domestic and one international joint ventures. Guided by a disciplined approach to capital allocation and aggressive asset management, the Company partners with premium brands such as Marriott^®, Ritz-Carlton^®, Westin^®, Sheraton^®, W^®, St. Regis^®, The Luxury Collection^®, Hyatt^®, Fairmont^®, Hilton^®, Swissôtel^®, ibis^® and Novotel^®, as well as independent brands. For additional information, please visit the Company’s website at www.hosthotels.com.

SOURAV GHOSH Chief Financial Officer (240) 744-5267

TEJAL ENGMAN Investor Relations (240) 744-5116 [email protected]

CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021.

Qualigen Therapeutics, Inc. Presentation Details are as follows:

Date:     Wednesday, March 17, 2021

Time:    3:00 pm EDT.

Management will be available throughout the day on March 17, 2021 for virtual one-on-one meetings.

Conference: Oppenheimer 31st Annual Healthcare Conference (virtual) will provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio & specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack^® System, which has been used successfully in diagnostics for 20 years. The Company’s cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS^™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational nucleolin-targeting DNA aptamer of ALAN, AS1411, is also a drug candidate for use in treating COVID-19 and other viral-based infectious diseases. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds.

Because Qualigen’s therapeutic candidates are still in the development stage, Qualigen’s only products that are currently commercially available are FastPack System diagnostic instruments and test kits, used in physician offices, clinics and small hospitals around the world. The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men’s health, hormone function, vitamin D status and antibodies against SARS-CoV-2. Qualigen’s facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.

For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/.

Forward-Looking Statements

This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. Actual events or results may differ from the Company’s expectations. For example, there can be no assurance that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company’s drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company’s owned and in-licensed patent applications; that such patents, if any, and the Company’s current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company’s prospective therapeutic products; that the Company will be able to maintain or expand market demand and/or market share for the Company’s diagnostic products generally, particularly in view of COVID-19-related deferral of patients’ physician-office visits and FastPack reimbursement pricing challenges; that adoption and placement of FastPack PRO System instruments (which are the only FastPack instruments on which the Company’s SARS-CoV-2 IgG test kits can be run) will be widespread; that the Company will be able to manufacture the FastPack PRO System instruments and SARS-CoV-2 IgG test kits successfully; that any commercialization of the FastPack PRO System instruments and SARS-CoV-2 IgG test kits will be profitable; or that the FDA will ultimately approve an Emergency Use Authorization for the Company’s SARS-CoV-2 IgG test. The Company’s stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company’s business (including events beyond the Company’s control, such as epidemics and resulting changes) can be found in the Company’s prior filings with the Securities and Exchange Commission, available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations:

David Kugelman, President and CEO
Atlanta Capital Partners, LLC
(404) 856-9157 Office
(866) 692-6847 Toll Free – U.S. & Canada
[email protected]

Tony Schor, President
Investor Awareness, Inc.
(847) 971-0922
[email protected]

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced that a large metropolitan housing authority in the U.S. has purchased samples of C-Bond Secure and C-Bond BRS (ballistic-resistant system) for evaluation to reinforce building glass to protect its residents against forced entry and gun violence.

C-Bond Secure is a multi-purpose glass strengthening primer and window film mounting solution. It was developed in partnership with one of the industry’s largest film suppliers to increase glass strength and glass flexibility. The product is compatible with any film manufacturers’ products in all film market segments including solar, safety, decorative, automotive, and marine. C-Bond Secure has thwarted break-in attempts and is proven to deter forced entry.

C-Bond BRS is a ballistic-resistant film system that consists of the patented C-Bond glass strengthening technology and security film. The C-Bond technology chemically bonds to the defects randomly distributed on the glass surface to increase impact resistance and prevent breakage. C-Bond BRS is validated by an independent third-party laboratory to provide National Institute of Justice (NIJ) Level I, Level IIA, Level II, and Underwriters Laboratories (UL) 752 ballistic-resistant protection. Video demonstrations of the product’s effectiveness can be found on the Company’s website.

“Our patented glass strengthening products are an important component of building security,” stated Scott R. Silverman, Chairman and CEO of C-Bond. “Reinforcing windows and glass doors to protect people where they live provides peace of mind and helps to minimize damage and harm to residents.”

C-Bond BRS has been installed in more than 80 schools, government buildings, media sites, and other high-security facilities around the country. C-Bond’s glass strengthening technology is protected by 22 patents and patent pending applications.

About C-Bond

C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented and patent-pending C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company’s Safety Solutions Group sells ballistic-resistant glass solutions directly to private enterprises, schools, hospitals, and government agencies. The Company also sells disinfection products, including MB-10 Tablets. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBondSys.

Forward-Looking Statements

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond’s ability to raise capital; the Company’s ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company’s and its customers’ ability to operate; the Company’s ability to source materials; the Company’s ability to retain key employees and consultants; as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on November 16, 2020, August 14, 2020, and May 15, 2020, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Allison Tomek
C-Bond Systems
6035 South Loop East 
Houston, TX 77033
[email protected]

Brokers and Analysts:
Chesapeake Group
410-825-3930
[email protected]

Located Post-Security, Terminal E, Operated by United Airlines

First XpresCheck in the State of Texas

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced in collaboration with United Airlines, the opening of its XpresCheck testing facility at Houston George Bush Intercontinental Airport.

XpresCheck’s pop-up testing facility is located in United’s Terminal E post-security. It has four separate testing rooms and an anticipated capacity to administer over 300 tests per day. COVID-19 testing options include the Rapid Molecular Test and the Polymerase Chain Reaction (PCR) Test.

Doug Satzman, XpresSpa CEO, said, “We are thrilled to be opening our first XpresCheck in Texas at Houston George Bush Intercontinental Airport. This testing facility extends our partnership with United and enables us to bring convenient and reliable COVID-19 testing options to their customers and employees.”

“Offering accessible and dependable testing solutions provides peace of mind to travelers and facilitates a safer in-flight experience,” said Rodney Cox, vice president of United’s Houston hub. “This new XpresCheck location will also help ensure our customers traveling through Houston meet the entry requirements at their final destination.”

About XpresSpa Group, Inc.

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at nine locations in seven airports: Boston Logan International Airport (2), Denver International Airport, Houston George Bush Intercontinental Airport, JFK International Airport, Newark Liberty International Airport (2), Phoenix Sky Harbor International Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com.

Twitter: 

@xprescheck

 and Instagram: 

@realxprescheck

About United Airlines

United’s shared purpose is “Connecting People. Uniting the World.” For more information, visit united.com, follow @United on Twitter and Instagram or connect on Facebook. The common stock of United’s parent, United Airlines Holdings, Inc., is traded on the Nasdaq under the symbol “UAL”.

Forward-Looking Statements

Forward-Looking Statements This press release may contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations as they become available, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today’s date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Investor Relations:

ICR
Raphael Gross
[email protected]
(203) 682-8253

Media:

Julie Ferguson
[email protected]
(312) 385-0098

United Airlines

David Gonzalez
[email protected]
832-671-8707

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Asia Broadband Inc. (OTC: AABB), a resource company focused on the production, supply and sale of precious and base metals, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Asia Broadband utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space. In recent months, the company has announced multiple exciting initiatives, most notably its acquisition of a high-potential mineral property in the state of Colima, Mexico, and its entry into a definitive development agreement to produce a white label gold-backed cryptocurrency coin.

As part of the Client Partner relationship with Asia Broadband, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Asia Broadband.

“We are pleased to engage IBN to maximize our communication with existing and potential shareholders while refining our overall messaging and outreach,” states James Gilbert, CEO of Asia Broadband.

With 15+ years of experience assisting 500+ client partners in improving communications within the investment community, and a sizable family of 50+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is uniquely positioned to provide Asia Broadband with the solutions needed to reach a wide audience of investors, consumers, journalists and the general public.

“Asia Broadband has given the investment community a lot to get excited about in recent months, announcing both its acquisition of a high-potential property in Colima, Mexico, and its development of the AABB Gold token in partnership with Core State Holdings Corp.,” states Chris Johnson, director of client solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for Asia Broadband as it works to advance these initiatives and capitalize on the forecast growth in the cryptocurrency space in the months ahead.”

To learn more about Asia Broadband, visit the company’s corporate newsroom profile at www.ibn.fm/AABB.

About
Asia Broadband
Inc.

Asia Broadband Inc. is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertical integration approach to sales transactions is the unique strength of AABB that differentiates the company and creates distinctive value for shareholders. The company is also releasing its freshly minted mine-to-token, gold-backed cryptocurrency AABB Gold token (AABBG) and expects to become a worldwide standard of exchange that is secured and trusted with gold backing, an outstanding quality relative to other cryptocurrencies. For more information, visit the company’s website at www.asiabroadbandinc.com.

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of Client Partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

For investor inquiries please use the following:

Email: [email protected]
Website: www.asiabroadbandinc.com
Phone: 702-866-9054

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) —

Safe-T® Group Ltd
. (NASDAQ, TASE: SFET), a provider of secure access solutions and intelligent data collection, announces today that its wholly owned subsidiary, Safe-T Data A.R Ltd., will host several  virtual technology events during March, in collaboration with its European partners, as follows:

Topic: “The Explosion of Cyber Attacks in 2020 and How to Prevent Them in 2021”

Safe-T Speaker: Eitan Bremler, Co-Founder & VP corporate Development

• March 10, 2021 at 11am (Israel time) – in collaboration with Softprom DACH, registration to the event is available here;
• March 11, 2021 at 12:00 (Israel time) – in collaboration with AERAsec Germany, registration to the event is available here.

Additional virtual events will be held by Safe-T in collaboration with its European partners in Italy, Switzerland, Netherlands, and Sweden.

Safe-T will also hold two events titled “To VPN or not to VPN”, in collaboration with its partners in Mexico and the UK.

The timing of these events, and registration details, will be provided separately on Safe-T’s website, www.safe-t.com

About Safe-T®

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of access solutions and intelligent data collection.

Our cloud and on-premises solutions mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Safe-T’s zero trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

The wide range of access solutions, empowered by our patented reverse-access technology and proprietary routing technology, reduce organizations’ attack surface, improve their ability to defend against modern cyberthreats and enable them smooth digital transformation and to safely migrate to the cloud.

We also offer intelligent data collection cloud service, based on our world’s fastest and most advanced & secured business proxy network which enables clients to collect accurate, transparent & sensitive data from public online sources.

Safe-T’s solutions on AWS Marketplace are available here

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses participation at future virtual events. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

Investor Relations Contacts

Chris Tyson     
Executive Vice President
MZ Group – MZ North America         
949-491-8235
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]